| Date | Title | Description |
| 24.10.2025 | smartbax Secures €4.7M to Combat Global Antibiotic Resistance Crisis | Munich-based biotech smartbax secured €4.7 million in pre-Series A funding. This capital fuels the fight against antibiotic resistance, a critical global health crisis. Smartbax develops innovative small-molecule antibiotics. Their pipeline... |
| 22.10.2025 | smartbax secures €4.7 million as Germany confronts 10,000 deaths a year from drug-resistant infections | smartbax, a Munich-based BioTech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful first closing of its €4.7 million pre-Series A financing round.
The round was led by new i... |
| 08.08.2025 | SNIPR BIOME Secures €35 Million to Revolutionize CRISPR-Medicine | Copenhagen's SNIPR BIOME clinched €35 million in Series B funding. This significant capital injection drives microbial CRISPR-medicine innovation. Funds target critical health challenges: developing CRISPR-Cas therapy for severe airway infe... |
| 08.08.2025 | Danish BioTech scale-up SNIPR Biome raises €35 million to target antimicrobial resistance in diseases like cancer | Copenhagen-based SNIPR Biome, a BioTech company innovating the development of microbial CRISPR-medicine, announced the close of a €35 million Series B raise to advance CRISPR-based therapies for cystic fibrosis airway infections, combat ant... |
| 07.08.2025 | SNIPR BIOME Raises EUR 35M in Series B Funding | SNIPR BIOME, a Copenhagen, Denmark-based company improving the development of microbial CRISPR-medicine, raised EUR 35M in Series B funding.
Backers included Cystic Fibrosis Foundation and the German Federal Agency for Breakthrough Innovati... |
| 17.07.2023 | Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing | Five contested patents held by SNIPR remain in place
Precedential ruling means that SNIPR's patent portfolio will not be subject to any further interference and will not be judged by the old first-to-invent standard
COPENHAGEN, Denmark, Jul... |
| 17.07.2023 | Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing | Precedential US Federal Court Decision Hands SNIPR Biome a win in patent appeal over Rockefeller University for CRISPR-Cas microbial gene editing
Mon, Jul 17, 2023 08:00 CET Report this content
Five contested patents held by SNIPR remain in... |
| 31.05.2023 | SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy | SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy
Wed, May 31, 2023 08:00 CET Report this content
SNIPR001 demonstrates proof of principle in reducing E. coli level... |
| 31.05.2023 | SNIPR Biome reports positive clinical interim results for groundbreaking, first-in-human, CRISPR-based microbial gene therapy | SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract
SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infectio... |
| 05.05.2023 | SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology | SNIPR001 is a novel CRISPR-Cas therapeutic designed to selectively target antibiotic resistant E. coli, which can cause fatal infections in vulnerable hematological cancer patients
SNIPR001 represents the first CRISPR- therapeutic developed... |
| 04.05.2023 | SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology | SNIPR Biome's data on first clinical drug candidate to prevent infections in hematological cancer patients published in Nature Biotechnology
Thu, May 04, 2023 17:07 CET Report this content
SNIPR001 is a novel CRISPR-Cas therapeutic designed... |
| 22.12.2022 | SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant | SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant
Thu, Dec 22, 2022 13:07 CET Report this content
SNIPR Biome further strengthens CRISPR/Cas IP portfolio with patent grant
Patent issuance adds to SNIPR’s extensive in... |
| 20.04.2022 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001 | COPENHAGEN, Denmark, April 20, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today announced dosing of the first human subjects in its phase 1 clinical trial with SNIPR001, an oral... |
| 20.04.2022 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001 | SNIPR BIOME Initiates First-in-Human Clinical Trial with SNIPR001
Wed, Apr 20, 2022 07:00 CET Report this content
Copenhagen, April 20th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome gene therapy biotechnology company, today annou... |
| 16.03.2022 | SNIPR BIOME expands its Executive Management team and opens offices in the US and UK | COPENHAGEN, Denmark, March 16, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today announced the appointment of Jasper Clube as Chief Intellectual Property Officer from 1 February 2022 and Step... |
| 16.03.2022 | SNIPR BIOME expands its Executive Management team and opens offices in the US and UK | SNIPR BIOME expands its Executive Management team and opens offices in the US and UK
Wed, Mar 16, 2022 07:00 CET Report this content
Copenhagen, March 16th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, today... |
| 08.03.2022 | SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark | SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark
Tue, Mar 08, 2022 07:00 CET Report this content
Copenhagen, March 8th, 2022: SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company,... |
| 08.03.2022 | SNIPR BIOME announces opening of new BSL2/GMO2-classified laboratory in Copenhagen, Denmark | COPENHAGEN, Denmark, March 8, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is opening a 175 square meter state-of-the-art BSL2/GMO2-classified laboratory in Copenhagen. The new facilities will... |
| 25.01.2022 | SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients. | SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients. Tue, Jan 25, 2022 14:54 CET
Copenhagen, January 25th, 2022: SNIPR BIO... |
| 25.01.2022 | SNIPR BIOME Announces U.S Food and Drug Administration grants Fast Track Designation for SNIPR001 for Prevention of Bloodstream Infections in Hematologic Cancer Patients | COPENHAGEN, Denmark, Jan. 25, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for SNIPR001. SNIPR001 is the ... |
| 11.01.2022 | SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections | SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections Tue, Jan 11, 2022 07:00 CET
Copenhagen, January 11th, 2022: SNIPR BIOME ApS... |
| 11.01.2022 | SNIPR BIOME Announces FDA Clearance of Investigational New Drug (IND) Application for SNIPR001, a Novel CRISPR Therapy Targeting Life-Threatening E. coli Infections | COPENHAGEN, Denmark, Jan. 11, 2022 /PRNewswire/ -- SNIPR BIOME ApS, a leading CRISPR and microbiome biotechnology company, is pleased to announce that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND)... |
| 09.12.2019 | These Danish tech startups raised maximum funding in 2019 | Among the many flourishing startup hubs across Europe, Denmark also has marked a space for itself, thanks to the several hundreds of tech startups based in the country. Entrepreneurs are benefited from low corporate tax rates and great leve... |
| 28.05.2019 | US patent grants strengthen SNIPR BIOME’s approach to enhance immuno-oncology outcomes by microbiome modulation | SNIPR BIOME today announced that the US Patent & Trademark Office has granted 2 patents covering concepts of shaping patients’ microbiomes to positively influence immuno-oncology therapies. The patents, US10,300,138 and US10,300,139 ent... |
| 11.03.2019 | Snipr raises $50M to use CRISPR to modulate the microbiome | Snipr Biome has raised (PDF) $50 million (€43 million, DKK320 million) to take CRISPR-based microbiome drugs into clinical trials. The Danish biotech is using CRISPR/Cas to selectively target and kill bacteria with specific DNA sequences.
S... |
| 11.03.2019 | Snipr raises $50M to use CRISPR to modulate the microbiome | Snipr Biome has raised (PDF) $50 million (€43 million, DKK320 million) to take CRISPR-based microbiome drugs into clinical trials. The Danish biotech is using CRISPR/Cas to selectively target and kill bacteria with specific DNA sequences.
C... |
| 11.03.2019 | SNIPR BIOME raises $50 million Series A financing to advance CRISPR-based microbiome drugs to human clinical trials | SNIPR BIOME, a leading CRISPR and microbiome private biotech company, today announced a $50 million series A financing led by existing investor Lundbeckfonden Emerge and LSP, together with North-East Family Office and Wellington Partners. S... |
| - | SNIPR Biome | “We are the CRISPR Microbiome Company; Our mission is to develop CRISPR-based medicines that give hope for effective and safe treatment of difficult-to-treat diseases in the future.” |
